Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

tetra logo

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Guy Chamberland

 

 

 

 

 

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.

Investor Presentation Deck
Tetra Investor Presentation




Related Articles

Consumer

American Premium Water Corp. (OTC: HIPH) Announces Sponsorship of NFL Draft Party Hosted by Star New York Jets Running Back Le’Veon Bell

April 30, 2019 admin Consumer, Newsmakers Comments Off on American Premium Water Corp. (OTC: HIPH) Announces Sponsorship of NFL Draft Party Hosted by Star New York Jets Running Back Le’Veon Bell

The event further establishes LALPINA CBD’s connection to professional athletes as the Company looks to penetrate the $30 billion US fitness market PLAYA VISTA, Apr 25, 2019  – American Premium Water Corporation(OTC: HIPH) announces that […]

Investor Presentations

FSD Pharma (CSE: HUGE) (OTC: FSDDF) Investor Presentation by Dr. Raza Bokhari New Green Frontier Cannabis Investor Conference

November 21, 2018 admin Investor Presentations Comments Off on FSD Pharma (CSE: HUGE) (OTC: FSDDF) Investor Presentation by Dr. Raza Bokhari New Green Frontier Cannabis Investor Conference

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 admin Healthcare, Newsmakers Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]